Risk of Mortality (Including Sudden Cardiac Death) and Major Cardiovascular Events in Atypical and Typical Antipsychotic Users: A Study with the General Practice Research Database
Year: 2013
Type: article
Study design: Observational Study
Abstract: Objective. Antipsychotics have been associated with increased cardiac events including mortality. This study assessed cardiac events including mortality among antipsychotic users relative to nonusers. Methods. The General Practice Research Database (GPRD) was used to identify antipsychotic users, matched general population controls, and psychiatric diseased nonusers. Outcomes included cardiac mortality, sudden cardiac death (SCD), all-cause mortality (excluding suicide), coronary heart disease (CHD), and ventricular arrhythmias (VA). Sensitivity analyses were conducted for age, dose, duration, antipsychotic type, and psychiatric disease. Results. 183,392 antipsychotic users (115,491 typical and 67,901 atypical), 544,726 general population controls, and 193,920 psychiatric nonusers were identified. Nonusers with schizophrenia, dementia, or bipolar disorder had increased risks of all-cause mortality compared to general population controls, while nonusers with major depression had comparable risks. Relative to psychiatric nonusers, the adjusted relative ratios (aRR) of all-cause mortality in antipsychotic users was 1.75 (95% CI: 1.64-1.87); cardiac mortality 1.72 (95% CI: 1.42-2.07); SCD primary definition 5.76 (95% CI: 2.90-11.45); SCD secondary definition 2.15 (95% CI: 1.64-2.81); CHD 1.16 (95% CI: 0.94-1.44); and VA 1.16 (95% CI: 1.02-1.31). aRRs of the various outcomes were lower for atypical versus typical antipsychotics (all-cause mortality 0.83 (95% CI: 0.80-0.85); cardiac mortality 0.89 (95% CI: 0.82-0.97); and SCD secondary definition 0.76 (95% CI: 0.55-1.04). Conclusions. Antipsychotic users had an increased risk of cardiac mortality, all-cause mortality, and SCD compared to a psychiatric nonuser cohort.
DOI: 10.1155/2013/247486
Authors: Tarita Murray-Thomas, Meghan E. Jones, Deven Patel, Elizabeth Brunner, Chetan C. Shatapathy, Stephen Motsko, Tjeerd P. Van Staa
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: antipsychotic drugs, sudden cardiac death, cardiac mortality, all-cause mortality, coronary artery disease, ventricular arrhythmias, atypical antipsychotics, typical antipsychotics, schizophrenia, bipolar disorder, major depressive disorder, dementia, mental illness, cardiovascular risk, drug safety, Clinical Practice Research Datalink, pharmacoepidemiology, matched controls, dose and duration
Open Access status: hybrid
Funders: Eli Lilly and Company, GlaxoSmithKline, Wellcome Trust, National Institute for Health and Care Research, Novo Nordisk UK Research Foundation, European Commission, College ter Beoordeling van Geneesmiddelen, Novo Nordisk, Top Institute Pharma, Medical Research Council, Health Technology Assessment Programme
OpenAlex ID: W2115053421
